On July 15, 2026, Bone Biologics Corporation postponed its 2026 annual meeting of stockholders from August 11, 2026, to September 28, 2026, at 11:30 a.m. ET. The postponement allows the company to include an additional proposal in its Definitive Proxy Statement and provides stockholders more time to review materials. The new record date for the meeting is August 6, 2026, and the deadline for stockholder submissions of director nominees or proposals is July 26, 2026. Bone Biologics Corporation is a biotechnology company that develops bone graft substitutes.

Bone Biologics Corporation priced a private offering of pre-funded warrants and Series F and G warrants to purchase 2,112,677 shares of common stock at a combined price of $1.419 per warrant. The offering generated approximately $2.7 million in net proceeds, with potential additional gross proceeds of $6 million if all warrants are exercised. Bone Biologics Corporation is a biotechnology company focused on developing bone biologics products.